{"id":"1499b351-998b-588a-8e65-03ec1b92d077","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-nr-pbmc","predicate":"increases_in_tested_regimen","statement":"Six weeks of NR increased PBMC NAD+ by approximately 60% relative to placebo; the NADP+ increase was not statistically significant.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"5144a6ff-9290-5999-a5f1-68b46d179434","mechanism_event_label":"NR raised NAD in sampled blood immune cells, while a matching rise in NADP was not established.","subject":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"object":{"id":"5d85872f-c88c-5e8b-a2c6-99a1eb636431","slug":"pbmc-nad-plus-content","display_name":"PBMC NAD+ content","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"5144a6ff-9290-5999-a5f1-68b46d179434","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-nr-pbmc-event","event_type":"observed_intervention","label":"NR raised NAD in sampled blood immune cells, while a matching rise in NADP was not established.","description":"Six weeks of NR increased PBMC NAD+ by approximately 60% relative to placebo; the NADP+ increase was not statistically significant.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"measured_pool","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"be6e4670-953f-5a4e-97da-1e536a54e0e4","slug":"nadp-plus","display_name":"NADP+","entity_type_key":"small_molecule"},"role":"separate_measured_pool","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"5d85872f-c88c-5e8b-a2c6-99a1eb636431","slug":"pbmc-nad-plus-content","display_name":"PBMC NAD+ content","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"Nicotinamide adenine dinucleotide, oxidized (measured_pool); Oxidized nicotinamide adenine dinucleotide phosphate (separate_measured_pool)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-clinical-sources/martens2018.txt\", \"locator\": \"Primary full report; exact character range, zero-based and end-exclusive\", \"file_sha256\": \"6743a5d9ad919ee67fb74af7f173b24bda66943d9c8878d6bc3bb72c80b2c37e\", \"start_char\": 14418, \"end_char\": 14971, \"text_sha256\": \"412dc909ef2a01bb3f0b5c429c6b594e084262779bbf4e6ad4005f0f1edb8767\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind crossover; 30 randomized, 24 healthy adults aged 55–79 completed","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nicotinamide riboside chloride 500 mg twice daily versus placebo, six weeks each","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small short trial, no formal washout, directional tests; secondary endpoints adjusted for multiple comparisons. PBMC NAD is not all-tissue NAD or evidence of lifespan extension.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"NR raised NAD in sampled blood immune cells, while a matching rise in NADP was not established.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[nia-clin-martens2018] Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. (2018). https://pubmed.ncbi.nlm.nih.gov/29599478/ DOI: 10.1038/s41467-018-03421-7","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Peripheral blood mononuclear cells and vascular physiology","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"c22107d4-f192-58b0-ad22-29fef2379609","evidence_kind":"source_excerpt","locator":"Lines 1459-1471","start_line":1459,"end_line":1471,"excerpt":"### nia-clin-nr-pbmc\nSix weeks of NR increased PBMC NAD+ by approximately 60% relative to placebo; the NADP+ increase was not statistically significant.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: NR raised NAD in sampled blood immune cells, while a matching rise in NADP was not established.\norganism: Homo sapiens\ntissue_or_cell_type: Peripheral blood mononuclear cells and vascular physiology\nexperimental_model: Randomized double-blind crossover; 30 randomized, 24 healthy adults aged 55–79 completed\nlimitations: Small short trial, no formal washout, directional tests; secondary endpoints adjusted for multiple comparisons. PBMC NAD is not all-tissue NAD or evidence of lifespan extension.\nexposure: Nicotinamide riboside chloride 500 mg twice daily versus placebo, six weeks each\ncross_nutrient: Nicotinamide adenine dinucleotide, oxidized (measured_pool); Oxidized nicotinamide adenine dinucleotide phosphate (separate_measured_pool)\nevidence_span: {\"source_cache\": \"artifacts/niacin-clinical-sources/martens2018.txt\", \"locator\": \"Primary full report; exact character range, zero-based and end-exclusive\", \"file_sha256\": \"6743a5d9ad919ee67fb74af7f173b24bda66943d9c8878d6bc3bb72c80b2c37e\", \"start_char\": 14418, \"end_char\": 14971, \"text_sha256\": \"412dc909ef2a01bb3f0b5c429c6b594e084262779bbf4e6ad4005f0f1edb8767\"}\n[nia-clin-martens2018] Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. (2018). https://pubmed.ncbi.nlm.nih.gov/29599478/ DOI: 10.1038/s41467-018-03421-7","model_system":"Randomized double-blind crossover; 30 randomized, 24 healthy adults aged 55–79 completed","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [nia-clin-martens2018] Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. (2018). https://pubmed.ncbi.nlm.nih.gov/29599478/ DOI: 10.1038/s41467-018-03421-7","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}